When it comes to MRD, AML ≠ ALL

Blood

Volumn 120, Issue 8, 2012, Pages 1536-1537

  Paietta, Elisabeth ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL; BONE MARROW CELL; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STEM CELL; CANCER SURVIVAL; CELL MATURATION; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; GENETIC RISK; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; NOTE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84865409622     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-435081     Document Type: Note

References (10)

1. Campana D. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? Curr Hematol Malig Rep. 2012;7(2):170-177.
2. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012;120(8):1581-1588.
3. Ossenkoppele GJ, van der Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol. 2011;153(4):421-436.
4. Rubnitz JE.MRDin AML: it's time to face the FACS. Blood. 2003;101(9):3341.
5. Paietta E. Minimal residual disease in AML: coming of age. Hematology Am Soc Hematol Educ Program. 2012; in press.
6. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
7. Pui C-H, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. New Engl J Med. 2009;360(26):2730-2741.
8. Leung W, Pui C-H, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468-472.
9. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-552.
10. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332-341.